Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 4/20 | 0.43 |
| ▸ | SELP | P16109 | 4/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.31 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.31 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.31 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.31 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077626 | 0.85 | SELE (0.34) | SELE | |
| SCHEMBL12240501 | 0.82 | SELE (0.46) | SELESELP | |
| SCHEMBL13657266 | 0.79 | SELE (0.65) | SELESELP | |
| SCHEMBL13969719 | 0.78 | SELE (0.51) | SELESELP | |
| SCHEMBL13657359 | 0.75 | SELE (0.43) | SELESELP | |
| SCHEMBL15214014 | 0.75 | SELE (0.65) | SELESELP | |
| SCHEMBL14823276 | 0.74 | SELE (0.71) | SELESELP | |
| SCHEMBL12240052 | 0.73 | SELE (0.52) | SELESELP | |
| SCHEMBL3006760 | 0.73 | SELE (0.57) | SELESELP | |
| SCHEMBL16257570 | 0.72 | SELE (0.69) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312278-A1 | TREATMENT OF CANCERS OF THE BLOOD USING SELECTED GLYCOMIMETIC COMPOUNDS | GLYCOMIMETICS , INC. (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312278-A1 | TREATMENT OF CANCERS OF THE BLOOD USING SELECTED GLYCOMIMETIC COMPOUNDS | BPGM, CD44, SIGLEC7 | SELE 64/4885SELP 74/4885LGALS3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.